Skip to main content
. 2017 Aug 31;35(1):121–130. doi: 10.1111/dme.13450

Figure 3.

Figure 3

The proportion of individuals with prediabetes requiring dose adjustment at week 12 according to (a) fasting triglycerides and (b) HDL cholesterol levels (intention‐to‐treat analysis). ALI, alirocumab; DM, diabetes mellitus; EZE, ezetimibe; PBO, placebo; Q2W, every 2 weeks; TG, triglycerides. Only individuals with at least 12 weeks of alirocumab treatment duration were included. Dose adjustment data for Pool 4 (no statin) are not presented as there was an administrative error during the MONO study (dose adjustment threshold of 1.8 mmol/l [70 mg/dl] instead of 2.6 mmol/l [100 mg/dl] was utilized).